Country: United States
Language: English
Source: NLM (National Library of Medicine)
ALTRENOGEST (UNII: 2U0X0JA2NB) (ALTRENOGEST - UNII:2U0X0JA2NB)
Bimeda, Inc.
ALTRENOGEST
ALTRENOGEST 2.2 mg in 1 mL
ORAL
PRESCRIPTION
INDICATIONS: OvaMed™ (altrenogest ) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season. CONTRAINDICATIONS: OvaMed™ (altrenogest ) Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Natural or synthetic gestagen therapy may exacerbate existing low-grade or “smoldering” uterine inflammation into a fulminating uterine infection in some instances.
OvaMed™ (altrenogest ) Solution 0.22% (2.2 mg/mL). Each mL contains 2.2 mg altrenogest in an oil solution. Available in 1000 mL plastic bottles. Manufactured for : Bimeda, Inc., Le Sueur, MN 56058 MADE IN USA ANADA # 200-481, Approved by FDA
Abbreviated New Animal Drug Application
OVAMED- ALTRENOGEST SOLUTION BIMEDA, INC. ---------- OVAMED™ (ALTRENOGEST) SOLUTION 0.22% (2.2 mg/mL) CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: OvaMed™ (_altrenogest_) Solution 0.22% contains the active synthetic progestin, altrenogest. The chemical name is 17α-allyl-17β-hydroxyestra-4,9,11-trien-3-one. The CAS Registry Number is 850-52-2. The chemical structure is: Each mL of OvaMed™ (_altrenogest_) Solution 0.22% contains 2.2 mg of altrenogest in an oil solution. ACTIONS: OvaMed™ (_altrenogest_) Solution 0.22% produces a progestational effect in mares. INDICATIONS: OvaMed™ (_altrenogest_) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season. CONTRAINDICATIONS: OvaMed™ (_altrenogest_) Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Natural or synthetic gestagen therapy may exacerbate existing low-grade or “smoldering” uterine inflammation into a fulminating uterine infection in some instances. PRECAUTIONS: Various synthetic progestins, including altrenogest, when administered to rats during the embryogenic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia. DOSAGE AND ADMINISTRATION: While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe (without needle). Draw out appropriate Read the complete document